Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T21:37:03.158Z.
Calculation as of: 2026-10-06T21:37:03.158Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76b79f67d555c15c1d19b9a53ec9076b1294dcb64452140a50102a9ec63499e7
PEG RATIO
N/A
GT Biopharma, Inc.
Market Cap
$8.04M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| GT Biopharma, Inc. (GTBP) | $8.04M | N/A |
| DataMEDS AI, Inc. (MEDS)vs › | $8.05M | N/A |
| HeartSciences Inc. (HSCS)vs › | $8.14M | N/A |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.87M | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.33M | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.67M | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.64M | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.46M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
